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BACKGROUND AND PURPOSE
The combination of Chinese herbs, Astragali Radix and Angelicae Sinensis Radix, could alleviate renal interstitial ﬁbrosis.
Astragaloside IV (AS-IV) and ferulic acid (FA) are the two major active constituents in this combination. In this study, we
employed rats with unilateral ureteral obstruction to determine whether AS-IV and FA have the same renoprotective effects
and investigated the mechanisms of this action.
EXPERIMENTAL APPROACH
Renal pathological changes were evaluated after treatment with AS-IV, FA or AS-IV + FA (AF) for 10 days. Meanwhile, the
expression of transforming growth factor b1 (TGF-b1), ﬁbronectin, a-smooth muscle actin (a-SMA), phosphorylation of c-Jun
NH2-terminal kinase (p-JNK) and nitric oxide (NO) production in kidney were determined. The expressions of ﬁbronectin,
a-SMA, mitogen-activated protein kinases [JNK, extracellular signal-regulated kinases (ERK), P38] in TGF-b1-treated NRK-49F
cells or interleukin-1-treated HK-2 cells after AS-IV, FA or AF were assessed.
KEY RESULTS
AF alleviated the inﬁltration of mononuclear cells, tubular atrophy and interstitial ﬁbrosis; reduced the expression of
ﬁbronectin, a-SMA, TGF-b1 and p-JNK; and dramatically increased the production of NO in obstructed kidneys. Neither AS-IV
nor FA alone improved renal damage, but both increased NO production. AF inhibited a-SMA and ﬁbronectin expression in
NRK-49F or HK-2 cells. Furthermore, AF signiﬁcantly inhibited IL-1b-induced JNK phosphorylation, without affecting ERK or
P38 phosphorylation. Neither AS-IV nor FA alone had any effect on the cells.
CONCLUSIONS AND IMPLICATIONS
AS-IV synergizes with FA to alleviate renal tubulointerstitial ﬁbrosis; this was associated with inhibition of tubular
epithelial–mesenchymal transdifferentiation (EMT) and ﬁbroblast activation, as well as an increase in NO production in
the kidney.
Abbreviations
A&A, the mixture of Astragali Radix and Angelicae Sinensis Radix; AF, the combination of astragaloside IV and ferulic
acid; AS-IV, astragaloside IV; CKD, chronic kidney disease; ECM, extracellular matrix; FA, ferulic acid; IL-1, interleukin-1;
MAPK, mitogen-activated protein kinase; TGF-b1, transforming growth factor-b1; UUO, unilateral ureteral obstruction;
a-SMA, a-smooth muscle actin
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Chronic kidney disease (CKD) is widely recognized as a major
public health problem that progressively develops to end-
stage renal disease (ESRD) irrespective of the underlying
cause. The persistent kidney injury induces renal inﬂamma-
tion, the overexpression of proﬁbrotic factors and myoﬁbro-
blast proliferation, followed by an exaggerated accumulation
of extracellular matrix (ECM) components, destruction of the
renal vasculature and ultimately renal ﬁbrosis (Hewitson,
2009). Although the systematic approach used to treat this
condition includes intensive reduction of blood pressure and
dietary restriction, this is not effective enough to completely
halt the progression of CKD (Ripley, 2009).
It is well accepted that tubulointerstitial ﬁbrosis is a better
indicator of the deterioration of renal function than glom-
erulosclerosis in renal diseases (Bohle et al., 1987). Inhibition
of tubulointerstitial ﬁbrosis has the potential to protect the
kidney from the deleterious effects of CKD. In the progression
of CKD, the activated interstitial ﬁbroblast or myoﬁbroblast is
central to the development of tubulointerstitial ﬁbrosis
(Strutz and Zeisberg, 2006). A number of pro-inﬂammatory,
proﬁbrotic cytokines, such as transforming growth factor-b1
(TGF-b1) (Schnaper et al., 2009), interleukin-1 (Fan et al.,
2001; Vesey et al., 2002) and connective tissue growth factor
(Chen et al., 2009), as well as angiotensin II (Gaedeke et al.,
2002) are released from the kidney in pathological condi-
tions. These factors converge and establish a ﬁbrogenic
context that drives the resident cells, including ﬁbroblasts (Qi
et al., 2006), pericytes (Lin et al., 2008), tubular cells (Kalluri
and Neilson, 2003) and endothelial cells (Zeisberg et al.,
2008), to transform into myoﬁbroblasts. The number of myo-
ﬁbroblasts is closely associated with the extent of tubuloint-
erstitial ﬁbrosis (Qi et al., 2006). Therefore, to intervene in the
transition of these cellular phenotypes is pivotal in inhibiting
tubulointerstitial ﬁbrosis.
In China, many Chinese herbal medicines have been
reported to slow down the progression of CKD (Li and Wang,
2005; Peng et al., 2005; Wojcikowski et al., 2006), including
Astragali Radix [the root of Astragalus membranaceus (Fisch.)
Bge. var. mongholicus (Bge.) Hsiao] and Angelicae Sinensis
Radix [the root of Angelia sinensis (Oliv.) Diels]. The combi-
nation of Astragali Radix and Angelicae Sinensis Radix was
demonstrated to possess a renoprotective effect in animal
models of CKD (Li et al., 1998; Wang et al., 2004; Zhang et al.,
2006a; Meng et al., 2007; Song et al., 2009), and this was
associated with a down-regulation of the expression of TGF-
b1, inhibition of the epithelial–mesenchymal transdifferentia-
tion (EMT), reduction of macrophage inﬁltration and
myoﬁbroblast proliferation, as well as an improvement in
endothelial dysfunction.
There are about 150 components in the decoction of
Astragali Radix and Angelicae Sinensis Radix (Xiao et al.,
1999). To identify the chemicals responsible for its renopro-
tective effects, we gradually reﬁned the mixture of the two
herbsaccordingtoitsabilitytoimprovetherenalpathological
damage (Zhao et al., 2010). Using mass spectrometry analysis,
we identiﬁed two major constituents, astragaloside IV (AS-IV)
and ferulic acid (FA), from an extract of Astragali Radix and
Angelicae Sinensis Radix, which preserve the antiﬁbrotic
effectsinratswithunilateralureteralobstruction(UUO).AS-IV
was reported to inhibit the adhesion of glomerular podocyte
dysfunction(Chenet al.,2008),alleviatetumornecrosisfactor
a (TNF-a)-induced endothelial cell apoptosis (Xu et al., 2006)
and improve the barrier function of the endothelial cell (Qu
et al., 2009). FA alleviates renal injury by decreasing urinary
protein excretion and inhibiting the overexpression of TGF-b1
(Fujita et al., 2008). Thus, AS-IV and FA may be the important
active constituents for inhibiting tubulointerstitial ﬁbrosis. In
thisstudy,wesoughttoidentifytherenalprotectiveefﬁcacyof
AS-IV and FA in obstructive nephropathy and to assess the
potential mechanisms of its renoprotective effects.
Methods
Drug preparation
AS-IV (Lot No. 110781-200512) and FA (Lot No. 0773-9910)
used in this study were of high purity (99%) as determined by
high performance liquid chromatography (HPLC) analysis
and were purchased from the National Institute for the
Control of Pharmaceutical and Biological Products (Beijing,
China). The compounds used in the cellular experiments
were dissolved in 1% DMSO (Sigma-Aldrich, St. Louis, MO,
USA) in a concentration of 2 mg·mL
-1 as a stock solution. The
stock solution was diluted with incubation medium when
used. The compounds were prepared as a suspension in the
medium before administration to the animals. We have
abbreviated the combination of AS-IV and FA to AF through-
out the manuscript. The mixture of Astragali Radix and
Angelicae Sinensis Radix (A&A) was prepared according to
the protocol in our earlier study (Meng et al., 2007). The
quality of A&A was controlled by HPLC-electrospray ioniza-
tion and mass spectrometry (Meng et al., 2010).
Animal and experimental protocol
All experiments were performed with approval from the
Animal Experimentation Ethics Committee of Peking Univer-
sity First Hospital. Male SPF Wistar rats (192  8 g) were
obtained from the Institute of Laboratory Animal Science,
Chinese Academy of Medical Sciences (Beijng). Animals were
allowed free access to water and standard rat chow. Animals
were housed at 25°C with 40% humidity with a 12/12 h
light/dark cycle. Animals were randomly divided into eight
groups as shown in Table 1. For the UUO groups, rats were
anaesthetized with sodium pentobarbital (40 mg·kg
-1, i.p.),
then the left ureter was exposed using a mid-abdominal inci-
sionandligatedwith3-0silksuture.Insham-operatedrats,the
ureterwasmobilizedbutnotligated.Thetestcompoundswere
administeredtotheratsbygavageonthedayoftheoperation.
Because 0.45–0.85 mg AS-IV and 0.2–0.5 mg FA were
determined·per gram dried weight of A&A, the low dose and
high dose of AS-IV and FA used in this study are equivalent to
the minimum and maximum contents determined in A&A.
Rats from each group were killed on day 10 after surgery.
Serum was obtained from the abdominal aorta blood after
centrifugation to detect serum creatinine and urea using a
Beckman Coulter LX20 Automated Analyzer (Beckman
Coulter Inc, Brea, CA, USA). The left kidneys were decapsu-
lated, washed with ice-cold normal saline, then rapidly
dissected. Coronal sections of 2–3 mm thick through the
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ﬁxed in 10% neutral buffered formalin; the rest was snap
froze in liquid nitrogen for further study.
Cell culture
Rat renal ﬁbroblasts (NRK-49F) were obtained from ATCC
(Manassas, VA). Cells were used between passages 3 and 15.
The cells were grown in culture dishes and maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and
100 U·mL
-1 penicillin and 100 mg·mL
-1 streptomycin. Equal
numbers of NRK-49F cells (2 ¥ 10
5) were cultured on 35 mm
dishes until 70–80% conﬂuence in 10% FBS-containing
medium and then changed to serum-free medium for 24 h.
Cells were pretreated with 0.1% DMSO, AS-IV (24 mmol·L
-1),
FA (43 mmol·L
-1) and AF (AS-IV 24 mmol·L
-1 + FA 43 mmol·L
-1),
respectively, for 30 min and then stimulated with TGF-b1
(1 ng·mL
-1) or incubation medium for 24 h. Human proximal
tubular epithelial cells (HK-2) were obtained from ATCC. The
cells were maintained in DMEM supplemented with 10% FBS.
Equal numbers of HK-2 cells (2 ¥ 10
5) were cultured on
35 mm dishes until 95% conﬂuence in 10% FBS-containing
medium and then changed to 0.2% fetal calf serum–
containing medium for 24 h. Cells were pretreated with 0.1%
DMSO, AS-IV (24 mmol·L
-1), FA (43 mmol·L
-1) and AF (AS-IV
24 mmol·L
-1 + FA 43 mmol·L
-1), respectively, for 30 min and
then stimulated with IL-1b (10 ng·mL
-1) or incubation
medium for 24 h.
Morphological and quantitative
image analysis
Sections were stained with haematoxylin and eosin (HE) and
Masson trichrome for morphological studies. Ten randomly
selected separate non-overlapping microscopic ﬁelds of each
kidney section were examined under the light microscope at
a magniﬁcation (¥200) and averaged to yield the score of each
kidney. Morphometric evaluation of the tubulointerstitial
area was performed by two authors under the direction of an
expert in experimental renal pathology. The renal pathology
of animals was assessed using a severity index (Radford et al.,
1997) that assigns points (0 to 3) for interstitial features of
kidney. The extents of interstitial ﬁbrosis, tubular atrophy
(deﬁned as luminal dilation and ﬂattened tubular epithelial
cells) and interstitial cell inﬁltration were semiquantitatively
scored as absent (0), involving less than 25% of the ﬁeld (1),
involving 26% to 50% of the ﬁeld (2) and involving greater
than 50% of the ﬁeld (3).
Immunohistochemistry
After formalin ﬁxation and parafﬁn embedding, 4 mm sec-
tions were deparafﬁnized in xylene and rehydrated through
graded ethanols. The endogenous peroxidase activity was
suppressed by exposing slide-mounted tissue to 0.3% H2O2
after antigen retrieval with pepsin or boiling. Sections were
then incubated with the following polyclonal antibodies
overnight at 4°C in phosphate-buffered saline: TGF-b1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), ﬁbronectin (Santa
Cruz Biotechnology), a-SMA (Zymed Laboratories, San Fran-
cisco, CA, USA). After being washed, slides were incubated
with biotinylated goat anti-rabbit IgG antibody and then
peroxidase conjugated streptavidin. Sections were visualized
with diaminobenzidine tetrahydrochloride (DAB) substrate
and counterstained with haematoxylin.
The expression of TGF-b1, ﬁbronectin or a-SMA in cortical
interstitium was assessed by spectrophotometry. The stained
sections were visualized on a computer display with an
Olympus DP50 camera connected to a light Olympus BX51
microscope (Olympus Optical Co., Tokyo, Japan) at an origi-
nal magniﬁcation of ¥200. The morphometric evaluation
consisted of quantitative analyses of TGF-b1, ﬁbronectin or
a-SMA by using speciﬁc software (Image-Pro Plus 6.0, Media
Cybernetics Inc. Bethesda, MD, USA). At least ten non-
overlapping ﬁelds at a magniﬁcation of ¥200 per section were
analysed for each animal. The expression of TGF-b1, ﬁbronec-
tin or a-SMA was assessed by the ratio of the mean positively
stained area to the mean whole area of the section.
Immunoﬂuorescence
After formalin ﬁxation and parafﬁn embedding, 4 mm sec-
tions were deparafﬁnized in xylene and rehydrated through
graded ethanols. Sections were then incubated with a mouse
monoclonal antibody of phosphorylation of c-Jun NH2-
terminal kinase (p-JNK, Santa Cruz Biotechnology) overnight
at 4°C in PBS. After being washed, slides were incubated with
Table 1
The groups of rats and their administrations in animal experiments
Group Abbreviation Administration
Sham-operated Sham Deionized water 3 mL·d-1
Unilateral ureteral obstruction UUO Deionized water 3 mL·d
-1
UUO + enalapril treatment Enalapril Enalapril: 4 mg·kg
-1·d
-1
UUO + A&A treatment A&A A&A: 12 g·kg-1·d-1
UUO + low-dose (AS-IV + FA) treatment AF-L AS-IV: 10.8 mg·kg
-1·d
-1 + FA 4.8 mg·kg
-1·d
-1
UUO + high-dose (AS-IV + FA) treatment AF-H AS-IV: 20.4 mg·kg
-1·d
-1 + FA 12 mg·kg
-1·d
-1
UUO + AS-IV treatment AS-IV AS-IV: 10.8 mg·kg-1·d-1
UUO + FA treatment FA FA: 4.8 mg·kg
-1·d
-1
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mouse IgG antibody. All sections were counterstained with
4′,6-diamidino-2-phenylindole.
Determination of renal tissue nitric
oxide (NO)
Kidney tissue (~100 mg) was pulverized using a chilled
mortar and pestle and then resuspended in 3 mL modiﬁed
radioimmunoprecipitation assay buffer containing 50 mM
Tris–HCl (pH 7.4), 1% NP-40, 0.25% Na deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethanesulphonyl
ﬂuoride, 1 mg·mL
-1 aprotinin, 1 mg·mL
-1 leupeptin, 1 mg·mL
-1
pepstatin, 1 mM Na3VO4, and 1 mM NaF. After being incu-
bated at 4°C for 1 h, the suspension was centrifuged (22 000¥
g, 4°C, 30 min), and the supernatant was aliquoted, frozen in
liquid nitrogen and stored at -80°C until use. The measure-
ment of NO in kidney homogenates was performed according
to a method described previously (Meng et al., 2007). Brieﬂy,
100 mL of the supernatant of kidney homogenates was incu-
bated with nitrate reductase, which converted nitrate to
nitrite, for 1 h at 37°C. Then, the samples were incubated for
10 min at room temperature after the addition of the Griess
reagent. The optical density values of the samples were mea-
sured at 530 nm on a spectrophotometer (Beckman DU530,
Beckman Coulter Inc, Brea, CA, USA). The concentration of
total nitrite, expressed as mmol·mg
-1 protein, represented NO
production in the homogenates.
Western blot analysis
Proteins in cell lysates were analysed by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) and
then electrophoretically transferred to nitrocellulose mem-
brane. The nitrocellulose membrane was blocked with 5%
skimmed milk in Tris-buffered saline–Tween-20 (TBS-T) for
1 h. The membrane was incubated with antibodies for
a-SMA, ﬁbronectin and mitogen-activated protein kinases
(MAPKs) diluted in 2% (w/v) BSA dissolved in TBS-T at 4°C
overnight. Blots were washed for 45 min in TBS-T before
incubation with a horseradish peroxidase (HRP)–conjugated
anti-rabbit or anti-mouse IgG for 2 h at room temperature
with rotation. Proteins were detected on X-ray ﬁlm using
chemiluminescence reagent plus (Perkin-Elmer Life Sciences,
Waltham, MA, USA).
RNA extraction and quantitative reverse
transcription–PCR analysis
Total RNA was isolated from the cultured cells by a simple
Total RNA Kit (Tinagen, Beijing, China) according to the
manufacturer’s instructions. Template cDNA was prepared
using a Reverse Transcription System A3500 (Promega,
Madison, WI) and quantiﬁed by real-time PCR using the
FastStart Universal SYBR Green Master (ROX) (Roche, India-
napolis, IN), with glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as an endogenous control for normalization.
Quantitative real-time PCR was performed using an ABI Prism
7500 Sequence Detection System (Applied Biosystems, Life
Technologies, Carlsbad, CA, USA). Brieﬂy, 1 mg of total RNA
was reverse-transcribed and subjected to PCR as follows: 95°C
for 10 min followed by 40 cycles at 95°C for 15 s, 60°C for
1 min. The primers used in this study were shown in Table 2.
Reaction speciﬁcity was conﬁrmed by melting curve analysis.
Gene expression proﬁles were normalized to GAPDH and
calculated using the DDCt (2
–DDCt) method for each sample.
Statistical analysis
Results are expressed as mean  SD. The results were assessed
by one-way analysis of variance (ANOVA) for comparisons
among groups. Differences between groups were determined
by Tukey’s multiple comparisons tests. Results were consid-
ered signiﬁcant when P < 0.05. All analyses were performed
with the SPSS14.0 statistical software package (SPSS Inc.,
Chicago, IL, USA).
Results
AF improved renal function and renal
interstitial injury
The serum creatinine and urea levels were higher in the UUO
group than that in the sham control group (P < 0.05) and
were all decreased after treatment with Enalapril, A&A, AF-H
or AF-L (P < 0.05). There was no difference between the AS-IV
or FA alone treated group and the UUO group. As shown in
Figure 1 and Table 3, the semiquantitative histomorphom-
etry analysis on HE- and Masson-stained sections revealed
signiﬁcant inﬁltration of mononuclear cells, damaged tubules
and interstitial ﬁbrosis in the obstructed kidneys, compared
with that in sham controls (P < 0.05). The pathological
changes were signiﬁcantly alleviated by AF (high or low
dose), with similar effects obtained with Enalapril or A&A
(P < 0.05), but there was no signiﬁcant change after treatment
with either AS-IV or FA alone.
AF alleviated the expression of ﬁbronectin,
a-SMA, TGF-b1 in obstructed kidneys
We examined the interstitial ﬁbronectin accumulation in
ﬁbrotic kidney after AS-IV and FA treatment. As a major
component of the ECM in the ﬁbrotic kidney, ﬁbronectin was
prominently stained in the tubulointerstitium of obstructed
kidneys compared with the sham-operated kidneys. The
Table 2
The primers of a-SMA, ﬁbronectin and GAPDH
Genes Primers
a-SMA
Sense 5′-CTTCCAGCCATCTTTCATTGG-3′
Antisense 5′-ATATCACACTTCATGATGCTGTTATAGGT-3′
Fibronectin
Sense 5′-TTATGACGACGGGAAGACCT-3′
Antisense 5′-GCTGGATGGAAAGATTACTC-3′
GAPDH
Sense 5′-TGCACCACCAACTGCTTAGC-3′
Antisense 5′-GGCATGGACTGTGGTCATGAG-3′
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Figure 1
Renal tubulointerstitial damage in obstructed kidneys. (A) Sham group. (B) UUO group. (C) UUO + Enarapril treatment. (D) UUO + A&A treatment.
(E) UUO + AF-L treatment. (F) UUO + AF-H treatment. (G) UUO + AS-IV treatment. (H) UUO + FA treatment. UUO: unilateral ureteral obstruction,
A&A: a decoction of Astragali Radix and Angelicae Sinensis Radix, AS-IV: astragaloside IV, FA: ferulic acid, AF-L: AS-IV & FA (low dose), AF-H: AS-IV
& FA (high dose).
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obstructive injury provoked a 7.5-fold induction of ﬁbronec-
tin (P < 0.05). Monotherapy with AS-IV or FA alone did not
attenuate the accumulation of ﬁbronectin, but AF treatment
resulted in a signiﬁcant reduction of ﬁbronectin (P < 0.05,
Figure 2).
The expression of a-SMA is the molecular hallmark of
myoﬁbroblasts. As shown in Figure 2, a-SMA was expressed
in the smooth muscle cells of renal arterioles but was rarely
evident in the tubulointerstitium of sham-operated kidneys.
Quantiﬁcation of immunostaining in renal tissue indicated a
striking increase in the a-SMA-positive area in the obstructed
kidneys compared with that in the sham control (P < 0.05),
and treatment with AF signiﬁcantly reduced interstitial
expression of a-SMA (P < 0.05).
TGF-b1 is an important pro-ﬁbrotic growth factor in the
progression of interstitial ﬁbrosis. As shown in Figure 2, there
was only occasional immunostaining of TGF-b1 in the tubular
cells of the sham-operated kidneys but diffuse staining in the
obstructive kidneys, especially the proximal tubular cells and
inﬁltrating monocyte/macrophage. The expression of TGF-b1
in the AF group was low in the epithelial cells of the dilated
tubuli. Semiquantitative analysis revealed that the expression
of TGF-b1 was signiﬁcantly increased in the UUO group com-
pared with the sham group (P < 0.05) and was decreased after
AF therapy compared with the UUO group (P < 0.05). Similar
to ﬁbronectin, AS-IV or FA treatment alone has no impact on
the expression of a-SMA and TGF-b1.
AF increased renal tissue NO production
Astragali Radix and Angelicae Sinensis Radix increased the
production of NO in obstructive kidneys via enhancement of
endothelial NOS activity (Meng et al., 2007). In this study, we
also evaluated the effect of AF on NO production. Figure 3
shows that the production of NO in obstructed kidney was
slightly increased compared with the sham controls, but this
was not statistically signiﬁcant. Monotherapy with AS-IV or
FA and the combination of the two constituents (AF) all
markedly increased the production of NO in obstructed
kidneys (P < 0.05).
AF inhibited TGF-b1-induced a-SMA and
ﬁbronectin expression in NRK-49F cells
During ureteral obstruction, interstitial ﬁbroblasts are acti-
vated resulting in massive proliferation and excessive ECM
accumulation. In this study, the expression of a-SMA and
ﬁbronectin protein in NRK-49F cells after stimulation with
TGF-b1 was signiﬁcantly higher than that in the cells treated
with DMSO (P < 0.05). AF dramatically inhibited a-SMA and
ﬁbronectin overexpression compared with TGF-b1-treated
cells (P < 0.05; Figures 4 and 5), but AS-IV or FA did not affect
the expression of a-SMA and ﬁbronectin after stimulation
with TGF-b1. Furthermore, it was shown that AF inhibited the
expression of a-SMA and ﬁbronectin mRNA in NRK-49 cells
treated with TGF-b1 (P < 0.05; Figures 6 and 7).
AF inhibited IL-1b-induced a-SMA and
ﬁbronectin expression and JNK
phosphorylation in HK-2 cells
IL-1b stimulates the transition of renal tubular epithelial cells
to myoﬁbroblasts via a TGF-b1-dependent pathway (Fan et al.,
2001). Our previous study showed that IL-1b induced HK-2
cells to express the myocyte biomarker a-SMA through the
activation of JNK and P38 signalling pathways (Zhang et al.,
2005). In this study, we evaluated the effects of AF on IL-1b-
stimulated HK-2 cells. The renal tubular epithelial cells dis-
played typical cobblestone morphology, but IL-1b induced
profound morphological changes, characterized by shape
elongation, dissociation from neighbouring cells and loss of
their cobblestone monolayer pattern. Simultaneous incuba-
tion of AF with IL-1b signiﬁcantly restored the morphology
Table 3
Renal function and tubulointerstitial injury of obstructed kidney in rats
Group n Creatinine (mmol·L-1) Urea (mmol·L-1)
Tubulointerstitial
injury index
Sham + vehicle 3 35.67  1.53 4.70  0.26 0.86  0.17
UUO + vehicle 3 72.33  4.50* 8.64  1.47* 9.70  0.95*
UUO + Enalapril 8 59.63  7.37*
# 7.81  1.39*
# 4.98  0.88*
#
UUO + A&A 8 51.36  2.97*
# 6.92  1.95*
# 6.95  0.95*
#
UUO + AF-L 8 48.50  3.42*
# 6.70  0.56*
# 5.97  1.07*
#
UUO + AF-H 8 49.00  6.87*
# 6.30  0.80*
# 5.62  1.23*
#
UUO + AS-IV 8 63.87  10.45* 8.67  1.32* 7.95  1.61*
UUO + FA 8 62.25  5.87* 7.51  0.42* 8.08  1.45*
AF reduces renal tubulointerstitial injury after UUO. Cellular inﬁltration, tubular atrophy and interstitial ﬁbrosis were observed 10 days after
UUO. Semiquantitative scoring of tubulointerstitial injury revealed more damage in UUO than in sham–treated kidneys and was improved
after treatment of enalapril, A&A or AF. Data are expressed as means  SD.
*P < 0.05 versus sham-operated rats;
#P < 0.05 versus UUO kidneys treated with vehicle.
UUO, unilateral ureteral obstruction; A&A, a decoction of Astragali Radix and Angelicae Sinensis Radix; AS-IV, astragaloside IV; FA, ferulic acid;
AF-L, AS-IV & FA (low dosage); AF-H, AS-IV & FA (high dosage).
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Figure 2
The expression of TGF-b1, a-SMA, ﬁbronectin in obstructed kidneys (immunohistochemistry, 200¥). (A) TGF-b1 in sham group. (B) TGF-b1i nU U O
group. (C) TGF-b1 in A&A treatment group. (D) TGF-b1 in AF-L treatment group. (E) a-SMA in sham group. (F) a-SMA in UUO group. (G) a-SMA
in A&A treatment group. (H) a-SMA in AF-L treatment group. (I) ﬁbronectin in sham group. (J) ﬁbronectin in UUO group. (K) Fibronectin in A&A
treatment group. (L) Fibronectin in AF-L treatment group. (M) Semiquantitative analysis of TGF-b1, a-SMA, ﬁbronectin expression in groups. UUO:
unilateral ureteral obstruction, A&A: a decoction of Astragali Radix and Angelicae Sinensis Radix, AF-L: astragaloside IV & ferulic acid (low dose).
Semiquantitative scoring of the expression of TGF-b1, a-SMA, ﬁbronectin revealed more damage in UUO than in sham–treated kidneys, which was
improved after treatment of A&A, or AF. Data are expressed as means  SD. *P < 0.05 versus sham-operated rats; #P < 0.05 versus UUO kidneys.
BJP
Herbal constituents inhibit renal ﬁbrosis
British Journal of Pharmacology (2011) 162 1805–1818 1811of the epithelial cells. As shown in Figures 8 and 9, IL-1b
signiﬁcantly increased a-SMA and ﬁbronectin expression in
HK-2 cells (P < 0.05). AF not only decreased the basal expres-
sion of a-SMA and ﬁbronectin in HK-2 cells but also signiﬁ-
cantly inhibited the expression of a-SMA and ﬁbronectin in
IL-1b-induced cells (P < 0.05). Monotherapy with AS-IV or FA
of HK-2 cells had no effect on the expression of a-SMA and
ﬁbronectin in either basal conditions or after IL-1b stimula-
tion. It was also shown that AF inhibits the expression of
a-SMA and ﬁbronectin mRNA in HK-2 cells stimulated with
IL-1b (P < 0.05; Figures 10 and 11).
We further examined whether AF decreased EMT through
the main MAPK signalling pathway, including JNK, extracel-
lular signal-regulated kinases (ERK) and P38. IL-1b signiﬁ-
cantly increased JNK, ERK and P38 phosphorylation, but AF
only signiﬁcantly inhibited IL-1b-induced JNK phosphoryla-
tion (P < 0.05, Figure 12), with no effect on ERK or P38
phosphorylation (data not shown).
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Figure 2
Continued.
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obstructed kidneys
Concomitant with the increased activity of JNK, the expres-
sion of p-JNK was conﬁrmed in obstructed kidneys using
immunoﬂuorescence. Normally, p-JNK is localized to some
tubular epithelial cells and occasional glomerular cells. UUO
induced a marked increase in JNK phosphorylation with
p-JNK staining prominent in dilated tubules, as well as
in interstitial cells. AF alleviated the expression of p-JNK
(Figure 13).
Discussion and conclusions
In this study, we examined the renoprotective effects of AS-IV
and FA, two active constituents of a mixture of Astragali
Figure 5
The expression of ﬁbronectin in NRK-49F cells. AS-IV: astragaloside
IV, FA: ferulic acid, AF: AS-IV and FA. AF decreased the expression of
ﬁbronectin in TGF-b1-treated cells (P < 0.05), but AS-IV or FA had no
effect on ﬁbronectin expression. Values are mean  SEM. *P < 0.05
versus DMSO-treated cells, #P < 0.05 versus TGF-b1-treated cells.
Figure 6
The expression of a-SMA mRNA in NRK-49F cells. AS-IV: astragalo-
side IV, FA: ferulic acid, AF: AS-IV and FA. AF decreased the expression
of a-SMA mRNA in TGF-b1-treated cells (P < 0.05). Values are mean
 SEM. *P < 0.05 versus control (DMSO-treated cells), #P < 0.05
versus TGF-b1-treated cells.
Figure 7
The expression of ﬁbronectin mRNA in NRK-49F cells. AS-IV: astraga-
loside IV, FA: ferulic acid, AF: AS-IV and FA. AF decreased the expres-
sion of ﬁbronectin mRNA in TGF-b1-treated cells (P < 0.05). Values are
mean  SEM. *P < 0.05 versus control, #P < 0.05 versus TGF-b1-
treated cells.
Figure 3
The production of NO in the obstructed kidneys. UUO: unilateral
ureteral obstruction, AS-IV: astragaloside IV, FA: ferulic acid, AF-L:
AS-IV and FA (low dosage). AS-IV and FA dramatically increased the
production of NO in obstructed kidneys (P < 0.05). NO production
was expressed as mmol·mg
-1 protein of NO2
- in the tissue. Values are
mean  SEM. *P < 0.05 versus UUO kidneys.
Figure 4
The expression of a-SMA in NRK-49F cells. AS-IV: astragaloside IV, FA:
ferulic acid, AF: AS-IV and FA. AF decreased the expression of a-SMA
in TGF-b1-treated cells (P < 0.05), but AS-IV or FA alone had not effect
a-SMA expression. Values are mean  SEM. *P < 0.05 versus DMSO-
treated cells, #P < 0.05 versus TGF-b1-treated cells.
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inhibit the progression of renal ﬁbrosis and improve renal
function in several animal models of kidney diseases (Li et al.,
1998; Wang et al., 2004; Zhang et al., 2006b; Meng et al.,
2007). The result indicated that the combination of AS-IV
and FA (AF) have renoprotective effects characterized by a
decrease in serum creatinine and urea, and a reduction in
tubulointerstitial ﬁbrosis in obstructive nephropathy, even
though neither AS-IV nor FA alone attenuated renal injury.
Renal interstitial ﬁbrosis is widely accepted as being closely
associated with the deterioration of renal function because
the tubulointerstitium comprises about 90% of the volume of
the kidney (Bohle et al., 1987). The prevention of interstitial
ﬁbrosis can signiﬁcantly slow the progression of kidney
disease. Thus, the combination of AS-IV and FA might be
beneﬁcial to the injured kidney.
UUO is recognized as an ideal experimental model of
renal interstitial ﬁbrosis. Ureteral obstruction leads to a sig-
niﬁcant reduction in renal blood ﬂow, local ischaemia/
hypoxia and an inﬂammatory response, followed by renal
interstitial myoﬁbroblast proliferation and ECM accumula-
tion in the renal interstitium (Chevalier et al., 2009). In the
process of renal ﬁbrosis, the overexpression of proﬁbrotic
cytokines (e.g. TGF-b1, CTGF) and inﬂammatory factors (such
as IL-b, TNF) contributes to kidney damage.
Notably, the proliferation of myoﬁbroblasts in renal tubu-
lointerstitium is the crucial event in the progression of renal
ﬁbrosis. The activation of resident ﬁbroblasts results in a
massive increase in the number of myoﬁbroblasts during the
early stage of obstructive nephropathy. From day 7 after ure-
teral obstruction, the transdifferentiation of epithelial and
endothelial cells becomes the major source of myoﬁbroblasts
(Grande et al., 2009). TGF-b1 plays a critical role in the initia-
tion and progression of renal ﬁbrosis (Qi et al., 2008). In
response to TGF-b1, resident ﬁbroblasts can be activated
(Suzuki et al., 2004), and tubular epithelial cells can trans-
differentiate into myoﬁbroblasts (Sebe et al., 2008). IL-1b
Figure 8
The expression of a-SMA in HK-2 cells. AS-IV: astragaloside IV, FA:
ferulic acid, AF: AS-IV and FA. AF decreased the expression of a-SMA
in IL-1b-treated cells (P < 0.05). Values are mean  SEM. *P < 0.05
versus DMSO-treated cells, #P < 0.05 versus IL-1b-treated cells.
Figure 9
The expression of ﬁbronectin in HK-2 cells. AS-IV: astragaloside IV, FA:
ferulic acid, AF: AS-IV and FA. AF decreased the expression of
ﬁbronectin in IL-1b-treated cells (P < 0.05). Values are mean  SEM.
*P < 0.05 versus DMSO-treated cells, #P < 0.05 versus IL-1b-treated
cells.
Figure 10
The expression of a-SMA mRNA in HK-2 cells. AS-IV: astragaloside IV,
FA: ferulic acid, AF: AS-IV and FA. AF decreased the expression of
a-SMA mRNA in IL-1b-treated cells (P < 0.05). Values are mean 
SEM. *P < 0.05 versus control (DMSO-treated cells), #P < 0.05 versus
IL-1b-treated cells.
Figure 11
The expression of ﬁbronectin mRNA in HK-2 cells. AS-IV: astragalo-
side IV, FA: ferulic acid, AF: AS-IV and FA. AF decreased the expression
of ﬁbronectin mRNA in IL-1b-treated cells (P < 0.05). Values are mean
 SEM. *P < 0.05 versus control, #P < 0.05 versus IL-1b-treated cells.
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tubule cells, inhibiting growth, a-SMA expression and
ﬁbronectin production, which are mediated by a TGF-b1-
dependent mechanism (Fan et al., 2001). In this study, we
investigated the effects of AS-IV and FA on two of the main
sources of myoﬁbroblasts, ﬁbroblasts and renal tubular epi-
thelial cells. Although treatment with either AS-IV or FA
alone had no effect, the combination of the two constituents
(AF) signiﬁcantly reduced the expression of a-SMA and
ﬁbronectin in activated ﬁbroblasts and tubular epithelial
cells. AF is thought to reduce the production of ECM resulting
in the inhibition of myoﬁbroblast proliferation.
The activation of MAPK signalling is an important
pathway in TGF-b1-mediated renal ﬁbrosis (Böttinger et al.,
2002). The three phosphorylation cascades of MAPKs
pathway, including ERK, JNK and p38 MAPK, participate in
TGF-b1 signalling cascades. These kinases can be activated
by growth factors and environmental stress leading to
alterations in cell growth and other key cell functions, such as
EMT (Rodrigues-Díez et al., 2008). Recently, JNK signalling
was reported to be involved in TGF-b1-induced EMT in
tubular epithelial cells (Mariasegaram et al., 2010). In other
epithelial cell types, including tracheal epithelial cells and
keratinocytes, TGF-b1 also induces EMT via JNK signalling
(Alcorn et al., 2008; Santibañez et al., 2006). In this study, the
inhibition of a-SMA and ﬁbronectin by AF was found to be
associated with the JNK pathway in the TGF-b1-treated NRK-
49F and IL-b-treated HK-2 cells. Thus, the activation of JNK
signalling may be an important pathway through which AF
induces an antiﬁbrotic effect in renal tubulointerstitial
ﬁbrosis.
AS-IV and FA have been found to inhibit the MAPK
pathway in several studies by other researchers. Either AS-IV
or FA was found to block the JNK pathway, but the doses used
in these experiments were higher than those used in the
present study. However, JNK activity is differentially regu-
lated by various protein kinases, including MKK4 and MKK7
(Fleming et al., 2000), mixed lineage kinases (Hirai et al.,
1997) and TGF-activated protein kinase 1 (Wang et al., 1997).
JNK1 activity has also been shown to be up-regulated as a
consequence of proteolytic cleavage of p21
WAF1/CIP1 (Shim
et al., 1996), and Ca
2+ and reactive oxygen species (ROS) gen-
eration play an important role in the activation of the JNK
pathway (Ham et al., 2006). AS-IV has been found to reduce
the increase in ROS (Xu et al., 2008), as well as prevent the
rise in intracellular [Ca
2+] (Hu et al., 2009). Also, FA was
shown to elevate the protein content of the JNK1 inhibitor
p21
WAF1/CIP1 (Hou et al., 2004). However, these effects of either
AS-IV or FA alone are not enough to inhibit the activation of
JNK at the doses used in our study, but when the actions of
these two compounds are combined, a synergistic effect is
produced that blocks the JNK pathway, induced by inhibition
of JNK activation and cleavage.
Our study also demonstrated that AS-IV and FA (AF)
increased NO production in the kidney. NO has been also
shown to ameliorate renal injury in kidney diseases (Tracht-
man et al., 1995; Huang et al., 2000). AS-IV has been reported
to enhance the activation of endothelial NO synthase (Zhang
et al., 2007), and FA has been shown to decrease oxidative
stress (Ma et al., 2010). Thus, AF not only increases eNOS
activation but also protects NO by increasing the activity of
scavenging ROS; these effects converge to increase NO pro-
duction and so promote the remission of interstitial ﬁbrosis.
Unfortunately, the positive role of AS-IV or FA alone on
renal ﬁbrosis was not observed at the doses of AS-IV or FA
used in this study. Higher doses were not used because the
range of concentrations of AS-IV or FA detected by HPLC
method was limited by the concentrations of Astragali Radix
and Angelicae Sinensis Radix available. Therefore, further
studies needed to observe the effects of AS-IV and FA at
different concentrations and to identify any other active
components in Astragali Radix and Angelicae Sinensis Radix
with renoprotective effects.
The mechanisms of renal ﬁbrosis are associated with a
series of dynamic pathological changes in the progression of
renal injury. In this study, we demonstrated that AF possesses
Figure 12
The expression of JNK in HK-2 cells. AS-IV: astragaloside IV, FA: ferulic acid, AF: AS-IV and FA. AF decreased JNK phosphorylation in IL-1b-treated
cells (P < 0.05). Values are mean  SEM. *P < 0.05 versus DMSO-treated cells, #P < 0.05 versus IL-1b-treated cells.
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Figure 13
The expression of p-JNK in obstructed kidneys (immunoﬂuorescence, 200¥). (A) p-JNK in sham group. (B) p-JNK in UUO group. (C) p-JNK in AS-IV
treatment group. (D) p-JNK in FA treatment group. (E) p-JNK in AF-L treatment group. UUO: unilateral ureteral obstruction, AS-IV: astragaloside
IV, FA: ferulic acid, AF: AS-IV & FA.
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inﬁltration, tubular atrophy and interstitial ﬁbrosis, as well as
inhibition of FN, a-SMA and TGF-b1 activity. Fibroblasts and
tubular epithelial cells are two important sources of myoﬁ-
broblasts; in vitro experiments were employed to explore the
potential cellular mechanisms of AF, but the cellular experi-
ments only demonstrated a small part of the complicated
process. Thus, we cautiously conclude that AF can alleviate
renal tubulointerstitial ﬁbrosis, and this is associated with
inhibition of tubular EMT and ﬁbroblast activation, as well as
an increase in NO production in the kidney.
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